Results 131 to 140 of about 1,973 (178)

Sevelamer-induced Gastrointestinal Mucosal Injury: A Critical Review for Clinicians. [PDF]

J Community Hosp Intern Med Perspect
Bathobakae L, Phuu P, Yasin S, Bashir R, Escobar J, Yuridullah R, Melki G, Elagami M, Amer K, Cavanagh Y, Baddoura W.   +10 more
europepmc   +1 more source

Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rats. [PDF]

Kidney360
Medicherla S, Reddy G, Gupta P, Chertow GM, Gupta S.   +4 more
europepmc   +1 more source

Maintaining functionality by graft interposition in a Brescia-Cimino arteriovenous fistula resembling an ulnar-basilic fistula. [PDF]

Kardiochir Torakochirurgia Pol
Papadoulas S, Leivaditis V, Tsimpoukis A, Stathopoulou M, Nikolakopoulos K, Papageorgopoulou C, Tasios K, Liolis E, Antzoulas A, Litsas D, Papadopoulos PD, Theofanis G, Katsakiori P, Papasotiriou M, Kitrou P, Mulita F.   +15 more
europepmc   +1 more source

Epidemiology of chronic dialysis treatment among children and adolescents in a capital of Northeastern Brazil. [PDF]

J Bras Nefrol
Medeiros IS, Siqueira JLA, Pires GASL, Santos ALGA, Santos RF.   +4 more
europepmc   +1 more source

Phosphorous metabolism and manipulation in chronic kidney disease. [PDF]

Nephrology (Carlton)
Marando M, Tamburello A, Salera D, Di Lullo L, Bellasi A.   +4 more
europepmc   +1 more source

A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis [PDF]

Nephrology Dialysis Transplantation, 2009
Sevelamer carbonate is an improved, buffered form of sevelamer hydrochloride developed for the treatment of hyperphosphataemia in CKD patients. Sevelamer carbonate formulated as a powder for oral suspension presents a novel, patient-friendly alternative to tablet phosphate binders.
Stanley Fan
exaly   +4 more sources

Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial

American Journal of Kidney Diseases, 2019
Hyperphosphatemia is associated with increased risk for chronic kidney disease (CKD) progression and reduced antiproteinuric effects of renin-angiotensin system (RAS) blockers. We investigated whether the phosphate binder sevelamer carbonate may enhance the antiproteinuric effect of RAS inhibitors in patients with CKD.Phase 2, randomized, controlled ...
Barbara Ruggiero, Matias Trillini, Lida Tartaglione   +2 more
exaly   +6 more sources

The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer [PDF]

Kidney International, 2007
Coronary artery calcification is more prevalent in dialysis patients than in patients without kidney disease and this is associated with high serum phosphorus. In this study, we evaluate the effect of calcium carbonate or sevelamer treatments on the progression of calcification in 90 predialysis patients.
Yuri Battaglia, V E Andreucci
exaly   +7 more sources

Some of the next articles are maybe not open access.

Related searches:

Sevelamer Carbonate

Annals of Pharmacotherapy, 2010
OBJECTIVE To review the pharmacology, pharmacokinetics, clinical efficacy, safety data, and place in therapy of sevelamer carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD).
Toros Kapoian
exaly   +3 more sources

Comparison of Sevelamer Hydrochloride and Sevelamer Carbonate: Risk of Metabolic Acidosis and Clinical Implications

Pharmacotherapy, 2009
Hyperphosphatemia is highly prevalent in patients with chronic kidney disease (CKD), particularly in those with advanced or end‐stage renal disease. Sevelamer hydrochloride is an ion‐exchange resin that reduces serum phosphorus concentrations. The agent also produces favorable lipid profile effects and does not cause hypercalcemia.
Brian Shepler
exaly   +3 more sources